The cell analysis global market is expected to reach $33,542.0 million by 2027 growing at a mid-single-digit CAGR from 2020 to 2027 due to rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery process, growing focusing on personalized medicine, the introduction of advanced technologies in single-cell analysis and emerging Asia-Pacific market. However, stringent government regulations, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.
The market for cell analysis is segmented based on technique, product, application, end-user and geography. The cell analysis techniques global market is segmented into PCR, Sequencing, Microfluidics and Microarrays, Spectrometry, Microscopy, Cytometry, High Content Analysis, Electrophoresis and Others. Among the techniques, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. Microfluidics and Microarrays segment is the fastest-growing segment at a high single-digit CAGR from 2020 to 2027.
The cell analysis products market is mainly segmented into consumables, instruments, software and services. Among these, consumables commanded the largest revenue in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. The consumables are further sub-segmented into reagents, assay kits, microplates, cell culture consumables and others. Among the consumables sub-segments, the Reagents held the largest share in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. Assay kits is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027. The software and services market is estimated to be $xx million in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027.
The instrument segment is further classified into cell counters, Cell microarray and microfluidics, liquid handling systems, cytometers, microfluidic devices, high content screening (HCS) systems microplate readers, PCR devices, sequencing instruments, spectrometers, microscopes and others. Among instruments, the PCR instruments commanded the largest share in 2020 and is expected to grow at a low single-digit CAGR from 2020 to 2027. This is attributed to extensive use of PCR (qPCR) use in diagnostics and also advancement in PCR systems, the launch of advanced PCR instruments, automated workflows, increasing approvals of PCR bases assays for medical diagnosis and other applications. Cell Microarrays and Microfluidics is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027 due to increasing advancements in microfluidic technologies mainly for single-cell analysis applications.
The application market is categorized by processes, by field, and by therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening. Cellular process application accounted for the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027 due to increasing cell-based research activities and an increase in funding. The sSingle-cell analysis market is the fastest-growing segment at a high single-digit CAGR from 2020 to 2027 due to increasing advancement in single-cell technologies. By field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. Diagnostics held the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027 due to the outbreak of various infectious diseases like influenza, Ebola, COVID-19 in recent years, adoption of early screening, companion diagnostic tests, prenatal screening of genetic diseases, and advancements in analytical tools, etc. Stem cell analysis is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027 due to increasing government support for stem cell-based research and also increasing approval of stem cell-based therapies. The cell imaging market is further segmented into live-cell imaging which commanded the revenue of $xx million in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027. By therapeutic area, the market is further segmented into cancer research, infectious disease, genetic testing, immunology, and others. The Infectious diseases accounted for the largest revenue in 2020 and is expected to grow at a low single-digit CAGR from 2020 to 2027 due to increasing incidence of infectious disease have raised the utilization of cell analytical technologies in research and as well as diagnosis. Cancer research is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027.
The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others. Hospitals & Diagnostic laboratories generated the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027. Contract Research Organizations is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027.
By geography, the cell analysis global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2020 and is expected grow at a mid single-digit CAGR from 2020 to 2027 due to increasing R&D expenditure, increasing funding for - cell-based research, increasing application cell analysis in drug discovery & development, increasing demand for personalized medicine; early disease detection, diagnosis and treatment, increasing focus in developing single-cell analysis technologies for various application in therapeutics, diagnostics and disease research.
The Asia-Pacific is the fastest-growing region in the cell analysis global market at a mid single-digit CAGR from 2020 to 2027 which is attributed to the increased scope for research activities in academic & research institutes, increasing outsourcing, increased incidence of chronic diseases (cancer) and infectious disease, increasing awareness about early screening (cancer) and prenatal test and their adoption in clinical care, increasing government and private investment for - cell-based research and also for the development & expansion single-cell analysis technologies and increasing number startup companies engaged in the development innovative solutions. However, lack of technical expertise, high cost of instruments, lack of skilled labors, and large scale clinical data challenges are some of the restraints for the cell analysis market in the region.
The cell analysis global market is competitive and all the players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the cell analysis global market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Illumine Inc. (U.S.), Merck KGAA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN & DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.5 PRIMARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment
3.3.1.2 Increasing government and private funding
3.3.1.3 Increasing advancements in cell imaging technologies reduce the cost and time consumption for the drug discovery process
3.3.1.4 Growing focus on personalized medicine
3.3.1.5 Introduction of advanced technologies in single-cell analysis
3.3.1.6 Emerging asia pacific cell analysis market
3.3.2 RESTRAINTS & THREATS
3.3.2.1 Lack of skilled personnel to use advanced cell analysis instruments
3.3.2.2 Expensive cell analysis instruments
3.3.2.3 Maintaining consistency, reproducibility of assays and lack of standardization
3.3.2.4 Stringent regulatory framework limits advancements in cellular analysis market
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN
3.5 FUNDING SCENARIO
3.6 CELL ANALYSIS – DEALS, ACQUISITIONS AND NEW PRODUCT LAUNCH
3.6.1 NEW PRODUCT LAUNCH
3.7 DEALS AND ACQUISITION
3.8 TECHNOLOGICAL ADVANCEMENTS
3.8.1 INTRODUCTION
3.8.2 CRISPER LIVE CELL IMAGING
3.8.3 SINGLE-CELL MULTI-OMICS
3.8.4 RAMAN LIVE CELL IMAGING
3.8.5 DROPLET-BASED MICROFLUIDICS IN SINGLE-CELL ANALYSIS
3.8.6 INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY IN SINGLE-CELL ANALYSIS (ICP-MS)
3.8.7 DEEP LEARNING AND AI IN MICROSCOPY
3.8.8 INTELLIGENT IMAGE-ACTIVATED CELL SORTING OR AI-DRIVEN CELL ISOLATION TECHNOLOGY
3.8.9 ADVANCED SPATIAL TECHNOLOGIES IN CELL ANALYSIS
3.8.10 DIGITAL MICROFLUIDIC ISOLATION OF SINGLE-CELLS FOR -OMICS (DISCO)
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 COMPETITIVE RIVALRY
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 BARGAINING POWER OF BUYERS
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10.1 CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS
3.10.2 MARKET SHARE ANALYSIS BY SINGLE-CELL ANALYSIS MAJOR PLAYERS
4 CELL ANALYSIS GLOBAL MARKET, BY TECHNIQUES
4.1 INTRODUCTION
4.1.1 PCR (POLYMERASE CHAIN REACTION)
4.1.2 SEQUENCING
4.1.3 MICROFLUIDICS AND MICROARRAYS
4.1.4 SPECTROMETRY
4.1.5 MICROSCOPY
4.1.6 CYTOMETRY
4.1.7 HIGH CONTENT SCREENING
4.1.8 ELECTROPHORESIS
4.1.9 OTHERS
5 CELL ANALYSIS GLOBAL MARKET, BY PRODUCTS
5.1 INTRODUCTION
5.2 CONSUMABLES
5.2.1 ASSAY KITS
5.2.2 REAGENTS
5.2.3 MICROPLATES
5.2.4 CELL CULTURE CONSUMABLES
5.2.5 OTHERS
5.3 INSTRUMENTS
5.3.1 CELL COUNTERS
5.3.2 CELL MICROARRAYS AND MICROFLUIDICS
5.3.3 LIQUID HANDLING SYSTEMS
5.3.4 CYTOMETERS
5.3.5 HIGH CONTENT SCREENING SYSTEMS
5.3.6 MICROPLATE READERS
5.3.7 PCR INSTRUMENTS
5.3.8 SEQUENCING INSTRUMENTS
5.3.9 SPECTROMETERS
5.3.10 MICROSCOPES
5.3.11 OTHER INSTRUMENTS
5.4 SOFTWARE AND SERVICES
6 CELL ANALYSIS GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 CELL ANALYSIS GLOBAL MARKET, BY PROCESS OF APPLICATION
6.2.1 CELLULAR PROCESSES
6.2.2 SIGNAL TRANSDUCTION PATHWAY
6.2.3 CIRCULATING TUMOR CELLS
6.2.4 SINGLE-CELL ANALYSIS
6.2.5 EPIGENETIC TARGET ANALYSIS
6.2.6 SUBPOPULATION CHARACTERIZATION
6.2.7 DRUG AND CANDIDATE SCREENING
6.3 CELL ANALYSIS GLOBAL MARKET, BY FIELD OF APPLICATION
6.3.1 FORENSICS
6.3.2 THERAPEUTICS
6.3.3 GENOMIC ANALYSIS
6.3.4 STEM CELL ANALYSIS
6.3.5 BIOMARKER RESEARCH
6.3.6 CELL IMAGING
6.3.6.1 LIVE-CELL IMAGING
6.3.7 DIAGNOSTICS
6.4 CELL ANALYSIS GLOBAL MARKET, BY THERAPEUTIC AREA OF APPLICATIONS
6.4.1 CANCER RESEARCH
6.4.2 GENETIC TESTING
6.4.3 INFECTIOUS DISEASES
6.4.4 IMMUNOLOGY
6.4.5 OTHERS
7 CELL ANALYSIS GLOBAL MARKET, BY END-USERS
7.1 INTRODUCTION
7.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
7.3 ACADEMIC & RESEARCH LABORATORIES
7.4 PHARMACEUTICALS AND BIOTECH COMPANIES
7.5 CONTRACT RESEARCH ORGANISATIONS
7.6 CELL BANKS
7.7 OTHERS
8 REGIONAL MARKET ANALYSIS
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 UNITED STATES OF AMERICA
8.2.2 REST OF NORTH AMERICA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 FRANCE
8.3.3 ITALY
8.3.4 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 REST OF APAC
8.5 REST OF THE WORLD
8.5.1 BRAZIL
8.5.2 REST OF LATIN AMERICA
8.5.3 MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 NEW PRODUCT LAUNCH
9.3 APPROVAL
9.4 AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS
9.5 ACQUISITIONS
9.6 OTHERS
10 MAJOR PLAYER PROFILES
10.1 AGILENT TECHNOLOGIES, INC.
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 BECTON DICKINSON AND COMPANY
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 BIO-RAD LABORATORIES, INC
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 DANAHER CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY.
10.4.6 SWOT ANALYSIS
10.5 ILLUMINA, INC.
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 MERCK KGAA
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 OLYMPUS CORPORATION
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 PERKINELMER, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 PROMEGA CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 QIAGEN N.V
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
10.11 THERMO FISHER SCIENTIFIC, INC.
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCT PORTFOLIO
10.11.4 KEY DEVELOPMENTS
10.11.5 BUSINESS STRATEGY
10.11.6 SWOT ANALYSIS
*If Applicable.